Girentuximab Withdrawn Phase 3 Trials for Renal Cancer / Renal Cell Carcinoma (RCC) Diagnostic

IndicationsStatusPurposePhase
WithdrawnDiagnostic3
clinicaltrials.gov IdentifierTitleDrugs
NCT01762592
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT